Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ketamine for Management of Neonatal and Pediatric Refractory Status Epilepticus.
Jacobwitz M, Mulvihill C, Kaufman MC, Gonzalez AK, Resendiz K, MacDonald JM, Francoeur C, Helbig I, Topjian AA, Abend NS. Jacobwitz M, et al. Among authors: resendiz k. Neurology. 2022 Sep 20;99(12):e1227-e1238. doi: 10.1212/WNL.0000000000200889. Epub 2022 Jul 11. Neurology. 2022. PMID: 35817569 Free PMC article.
Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study.
Petersenn S, Bollerslev J, Arafat AM, Schopohl J, Serri O, Katznelson L, Lasher J, Hughes G, Hu K, Shen G, Reséndiz KH, Giannone V, Beckers A. Petersenn S, et al. Among authors: resendiz kh. J Clin Pharmacol. 2014 Nov;54(11):1308-17. doi: 10.1002/jcph.326. Epub 2014 May 24. J Clin Pharmacol. 2014. PMID: 24800725 Clinical Trial.
Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study.
Wolin EM, Hu K, Hughes G, Bouillaud E, Giannone V, Resendiz KH. Wolin EM, et al. Among authors: resendiz kh. Cancer Chemother Pharmacol. 2013 Aug;72(2):387-95. doi: 10.1007/s00280-013-2202-1. Epub 2013 Jun 14. Cancer Chemother Pharmacol. 2013. PMID: 23765178 Free PMC article. Clinical Trial.
Pasireotide (SOM230), a novel multireceptor-targeted somatostatin analogue, is well tolerated when administered as a continuous 7-day subcutaneous infusion in healthy male volunteers.
Petersenn S, Unger N, Hu K, Weisshaar B, Zhang Y, Bouillaud E, Reséndiz KH, Wang Y, Mann K. Petersenn S, et al. Among authors: resendiz kh. J Clin Pharmacol. 2012 Jul;52(7):1017-27. doi: 10.1177/0091270011408727. Epub 2011 Jun 14. J Clin Pharmacol. 2012. PMID: 21673137 Clinical Trial.